Is at least 18 years of age and the local legal age of consent for clinical studies when signing the informed consent form (ICF).
Has documented baseline mean platelet count of \<30 x 10\^9/L before randomization
Has a documented duration of primary immune thrombocytopenia (ITP) of more than 12 months on the date of informed consent form (ICF) signature.
Has documented prior ITP treatment with at least 1 of the following treatments: corticosteroids, intravenous immunoglobulin (IVIg), anti-D immunoglobulin, thrombopoietin receptor agonist (TPO-RAs), or rituximab.
Has documented insufficient response to a prior ITP treatment (the specific criteria can be found in the protocol).
Has documented prior response defined as 1 platelet count of ≥50 × 109/L to at least 1 of the following ITP treatments in the 3 years before the date of ICF signature: prednisone, dexamethasone, other or nonspecified corticosteroids, IVIg, or anti-D immunoglobulin
You may not be if
Other than the indication under study, known autoimmune disease or any medical condition that would interfere with an accurate assessment of clinical symptoms of ITP, confound the results of the study or put the participant at undue risk.
Secondary ITP
Nonimmune thrombocytopenia
Autoimmune hemolytic anemia
ITP-associated critical or severe bleeding The complete list of criteria can be found in the protocol.
Clareo Health | A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
